WP
MRTX

Woodline Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Woodline Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-278,223
Closed -$12.1M – 703
2023
Q3 		$12.1M Sell
278,223
-95,109
-25% -$3.4M 0.14% 199
2023
Q2 		$13.5M Buy
373,332
+107,232
+40% +$4.42M 0.16% 172
2023
Q1 		$9.89M Sell
266,100
-370,617
-58% -$16.7M 0.13% 201
2022
Q4 		$28.8M Buy
636,717
+414,209
+186% +$26.8M 0.39% 61
2022
Q3 		$15.5M Sell
222,508
-71,059
-24% -$5.26M 0.22% 139
2022
Q2 		$19.7M Buy
293,567
+167,519
+133% +$10.7M 0.3% 98
2022
Q1 		$10.4M Buy
126,048
+1,156
+0.9% +$118K 0.17% 170
2021
Q4 		$18.3M Buy
124,892
+11,749
+10% +$1.82M 0.26% 115
2021
Q3 		$20M Buy
113,143
+18,867
+20% +$3.04M 0.33% 84
2021
Q2 		$15.2M Buy
94,276
+63,173
+203% +$10.1M 0.28% 95
2021
Q1 		$5.33M Buy
+31,103
New +$6.16M 0.12% 186
2020
Q3 		– Sell
-51,742
Closed -$5.91M – 222
2020
Q2 		$5.91M Sell
51,742
-49,211
-49% -$4.77M 0.23% 101
2020
Q1 		$7.76M Buy
+100,953
New +$9.05M 0.55% 59

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Woodline Partners's MRTX Position: Q4 2023 in Review

Woodline Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 278,223 shares — an estimated $12.1M sold.

Woodline Partners first reported a position in MRTX in Q1 2020 and held it in 13 quarters. The position peaked at $28.8M in Q4 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Woodline Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Woodline Partners sold 278,223 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $12.1M.
  • Woodline Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 13 quarters.
  • Woodline Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $28.8M in Q4 2022.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Woodline Partners's 13F filing for Q4 2023, filed 14 Feb 2024.